Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17319218 | 0.86 | SMN1; SMN2 (0.60) | TDP1SMN1; SMN2HTTPOLBKMT2A | |
| SCHEMBL7834037 | 0.83 | ALDH1A1 (0.48) | TDP1SMN1; SMN2HTTPOLBTSHR | |
| SCHEMBL22433208 | 0.83 | CA12 (0.58) | TDP1SMN1; SMN2HTTPOLBKMT2A | |
| SCHEMBL801402 | 0.83 | POLB (0.52) | TDP1SMN1; SMN2HTTPOLBKMT2A | |
| SCHEMBL10700475 | 0.80 | POLB (0.63) | SMN1; SMN2HTTPOLBKMT2ATSHR | |
| SCHEMBL634315 | 0.79 | CA12 (0.61) | TDP1SMN1; SMN2POLBALDH1A1L3MBTL1 | |
| SCHEMBL32664495 | 0.79 | CA12 (0.61) | TDP1SMN1; SMN2POLBALDH1A1L3MBTL1 | |
| SCHEMBL4618631 | 0.77 | SFRP1 (0.76) | TDP1SMN1; SMN2HTTPOLBKMT2A | |
| SCHEMBL17319511 | 0.77 | ALDH1A1 (0.56) | TDP1SMN1; SMN2HTTPOLBKMT2A | |
| SCHEMBL16261330 | 0.76 | CNR2 (0.50) | HTTPOLBKMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569285-B2 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GABRA1, GRM1, GABRA5 | TDP1 2079/4885SMN1; SMN2 2283/4885HTT 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.